News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus
Photo from Erman Akkus/X
May 24, 2024, 14:27

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“First-line mFOLFIRINOX for GI high-grade neuroendocrine neoplasms?

  • ORR: 77% (complete response: 3%; partial response: 74%)
  • mPFS: 12 months
  • mOS: 20.6 months

Retrospective, n=35.

Prospective clinical trials are needed, may be considered in patients with high tumor burden and who can tolerate.”

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman AkkusFirst-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

 

Read further.
Source: Erman Akkus/X

Ankara University cancer Erman Akkus First-line mFOLFIRINOX high grade neuroendocrine neoplasms high tumor burden mFOLFIRINOX OncoDaily Oncology Prospective clinical trials
Special Coverage
Insight
Dec 22, 2024, 00:21
Eric J. Small: ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe